Search clinical trials for: PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab

Total 938 results

XIANG YANQUN

Active, not recruiting

Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study

Chemotherapy Effect | Metastatic Nasopharyngeal Carcinoma

China
The Second Affiliated Hospital of Shandong First...

Recruiting

Clinical Study of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Xiangya Hospital of Central South University
Wu Jieping Medical Foundation

Recruiting

Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain Metastases

Non-small Cell Lung Cancer Metastatic | Brain Metastases

China
Shanghai Chest Hospital

Not yet recruiting

Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE) (RICE)

Chemotherapy | Immunotherapy | Concurrent Chemoradiotherapy | Esophageal Squamous Cell Carcinomas
Second Affiliated Hospital, School of Medicine,...

Recruiting

Single-center, Prospective Cohort Study of PD-1 Inhibitors on Clinical Outcomes of Carotid Plaques in Tumor Patients

Carotid Artery Plaque | Pd-1 Inhibitors

China
Henan Cancer Hospital

Active, not recruiting

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

HER2 Positive Metastatic Breast Cancer

China
First People's Hospital of Hangzhou
Hangzhou Cancer Hospital

Recruiting

SBRT Combined With PD-1 Inhibitor and Thoracic Hyperthermia for Advanced NSCLC

Stereotactic Body Radiation Therapy; PD-1 Inhibitor; Hyperthermia; NSCLC

China
Pengyuan Liu
Zhejiang Hospital

Completed

Hyperthermia Combined With Immune Checkpoint Inhibitor Therapy for Advanced Gastrointestinal Tumours (HEAIS001)

Gastrointestinal Tumor

China
Yongchang Zhang

Recruiting

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

HER2 Insertion Mutation Positive Advanced NSCLC

China
Hunan Cancer Hospital

Completed

Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer

Colorectal Cancer

China
Fudan University

Not yet recruiting

Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy

NSCLC Stage IV

China
Tongji Hospital
National Natural Science Foundation of China

Recruiting

Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study (NICCE)

Esophageal Squamous Cell Carcinoma | Neoadjuvant Therapies

China
Beijing Friendship Hospital

Recruiting

Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer

Locally Advanced Rectal Cancer

China
Dong Wang

Not yet recruiting

TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer (TC)

ESCC

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

HCC

China
Tongji Hospital
Wuhan University; Sun Yat-sen University; Wuhan Union Hospital, China

Suspended

Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Hutchison Medipharma Limited

Recruiting

Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

Extensive-Stage Small Cell Lung Cancer

China
Qingdao Central Hospital

Recruiting

Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer

Metastatic Esophageal Squamous Cell Carcinoma

China
Jounce Therapeutics, Inc.

Completed

Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies

Cancer

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection

Hepatocellular Carcinoma | Graft Rejection | Immunotherapy | Immune Checkpoint Inhibitor

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
Canadian Cancer Trials Group
Melanoma and Skin Cancer Trials Limited

Recruiting

Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)

Unresectable/Metastatic Melanoma

Canada, Australia
Second Affiliated Hospital, School of Medicine,...

Recruiting

A Perspective, Self-control Study on the Progression of Carotid Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up

Carotid Artery Plaque | Plaque, Atherosclerotic | Immune Checkpoint Inhibitors | Programmed Cell Death Protein 1 Inhibitor | Intimal Medial Thickness of Internal Carotid Artery

China
Shanghai First Maternity and Infant Hospital

Unknown

Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer (ECCT)

Endometrial Cancer Stage I
Hunan Province Tumor Hospital

Completed

The Prediction Biomarkers of Survival Outcome for Severe Immune-related Hepatitis

Lung Cancer

China
Zhongda Hospital

Recruiting

TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC (CHANCE2202)

Hepatocellular Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

Gastric Cancer
Second Affiliated Hospital, School of Medicine,...
Zhejiang Cancer Hospital; Sun Yat-sen University; Ningbo Medical Center Lihuili... and other collaborators

Recruiting

Multi-center Observational Study on the Progression of Atherosclerotic Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up

Plaque, Atherosclerotic | Programmed Cell Death Protein 1 Inhibitor

China
Fudan University

Active, not recruiting

Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.

Metastatic Esophageal Squamous Cell Carcinoma

China
Zhongda Hospital

Recruiting

TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC (CHANCE2201)

Hepatocellular Carcinoma

China
Qingdao Central Hospital

Recruiting

Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer

Overall Survival

China
Sun Yat-sen University

Recruiting

Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC

Esophageal Squamous Cell Carcinoma | Oligometastatic Disease

China
Peking Union Medical College

Recruiting

Neoadjuvant Immunotherapy With Chemotherapy for Stage I-IIIB Non-Small Cell Lung Cancer Patients

Non-small Cell Lung Cancer

China
Istari Oncology, Inc.

Active, not recruiting

LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

Melanoma

United States
Fudan University

Recruiting

Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor

Esophageal Squamous Cell Carcinoma | Oligometastatic Disease | Radiotherapy

China
Peking University Cancer Hospital & Institute
Innovent Biologics (Suzhou) Co. Ltd.

Completed

HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma

Liver Metastases | Esophageal Squamous Cell Carcinoma | Hepatic Arterial Infusion Chemotherapy

China
Sun Yat-sen University

Completed

Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Qingdao Central Hospital

Recruiting

Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC

PFS | OS

China
Ruihua Xu

Recruiting

Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer

Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma

China
Women's Hospital School Of Medicine Zhejiang University

Recruiting

Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy

Gestational Trophoblastic Neoplasia

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Affiliated Hospital of Jinan University; Shenzhen University General...

Recruiting

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Carcinoma | Digestive System Neoplasms | Intrahepatic Cholangiocarcinoma | First-line Treatment | PD-1 Inhibitor

China
Sun Yat-sen University

Recruiting

Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical Trial (AIPD-1)

Hepatocellular Carcinoma

China
The First Hospital of Jilin University

Not yet recruiting

CT and MRI in Prediction of Response in Patients With Gastric Cancer Following Neoadjuvant Chemotherapy and/or Immunotherapy

Gastric Cancer | Magnetic Resonance Imaging | Neoadjuvant Chemotherapy | Neoadjuvant Immunotherapy | Tomography, X-Ray Computed
Ruijin Hospital

Not yet recruiting

PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT

Lymphoma, Large B-Cell, Diffuse | Chemotherapy | Transplantation

China
Fujian Cancer Hospital

Not yet recruiting

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

NSCLC Stage IV

China
The First Affiliated Hospital of Guangdong Pharmaceutical...
Guangzhou Anjie Biomedical Technology Co., Ltd.

Unknown

CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer

Advanced Esophageal Cancer

China
Grit Biotechnology

Not yet recruiting

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Squamous Cell Carcinoma

HNSCC | Adults

China
Third Affiliated Hospital, Sun Yat-Sen University

Recruiting

Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer

Colorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
Ruijin Hospital

Recruiting

PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT

Lymphoma, Large B-Cell, Diffuse | Chemotherapy | Transplantation

China

Search clinical trials for: PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations